A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

References

• Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183–195.
   Web of Science ®Google Scholar
• BHIVA guidelines for the treatment of HIV-1-positive adults with ART 2015. Interim update. https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines-2016-interim-update.pdf. Updated 2016. Accessed August 8, 2021.
   Google Scholar
• Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Updated March 17, 2019. Accessed August 8, 2021.
   Google Scholar
• Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (WHO/CDS/HIV/18.5). https://apps.who.int/iris/bitstream/handle/10665/277395/WHO-CDS-HIV-18.51-eng.pdf?ua=1. Published 2018. Updated March 17, 2019.
   Google Scholar
• Viread summary of product characteristics. https://www.medicines.org.uk/emc/product/1615/smpc. Published 2021. Accessed August 8, 2021.
   Google Scholar
• Verhelst D, Monge M, Meynard J-L, Fouqueray B, Mougenot B, Girard P-M, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40(6):1331–1333.
   Web of Science ®Google Scholar
• Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070–1073.
   PubMed Web of Science ®Google Scholar
• Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. Aids. 2003;17(6):935–937.
   PubMed Web of Science ®Google Scholar
• Horberg M, Tang B, Towner W, Piketty C, Kazatchkine M, Nochy D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. JAIDS J Acquir Immune Defic Syndr. 2010;53(1):62–69.
   Web of Science ®Google Scholar
• Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 2016;18(2):59–68.
   PubMed Web of Science ®Google Scholar
• Ezinga M, Wetzels JF, Bosch ME, van der Ven AJ, Burger DM. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Antivir Ther. 2014;19(8):765–771.
   PubMed Web of Science ®Google Scholar
• Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella FJ, et al. HIV infection, tenofovir, and urine α1-microglobulin: a cross-sectional analysis in the multicenter AIDS cohort study. Am J Kidney Dis. 2016;68(4):571–581.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Mutoh Y, Kawasaki Y, Tomonari K, Kikuchi Y, Gatanaga H, et al. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. Aids. 2018;32(2):179–188.
   Web of Science ®Google Scholar
• Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. JAIDS J Acquir Immune Defic Syndr. 2016;72(1):58–64.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate. AIDS. 2019;33(9):1455–1465.
   PubMed Web of Science ®Google Scholar
• Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231.
   Google Scholar
• Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67(3):411–419.
   PubMed Web of Science ®Google Scholar
• Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387–2391.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666–e676. Oct
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389.
   PubMed Web of Science ®Google Scholar
• Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Eradic. 2018;4(2):72–79.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907–1915.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy . J Infect Dis. 2008;197(1):102–108.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Stellbrink H-J, Compston J, Orkin C, Arribas JR, Domingo P, et al. 96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18(7):905–913.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, DeJesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1–infected patients: 156-week results From STARTMRK. Clin Infect Dis. 2011;53(8):807–816.
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743. Mar
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection. JAIDS J Acquir Immune Defic Syndr. 2013;63(1):96–100.
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. Aids. 2005;19(17):2031–2033.
   Web of Science ®Google Scholar
• Papaleo A, Warszawski J, Salomon R, Jullien V, Veber F, Dechaux M, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J. 2007;26(10):949–951.
   Web of Science ®Google Scholar
• Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, et al. Urinary β2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22(8):744–748.
   Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, de Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667–1678.
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207(9):1359–1369.
   PubMed Web of Science ®Google Scholar
• Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis. 2012;44(9):689–696.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12(3):e1001809.
   PubMed Web of Science ®Google Scholar
• Vrouenraets SME, Fux CA, Wit FWNM, Garcia EF, Furrer H, Brinkman K, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. Aids. 2011;25(17):2149–2155.
   Web of Science ®Google Scholar
• Burling KA, Cutillas PR, Church D, Lapsley M, Norden AGW. Analysis of molecular forms of urine retinol-binding protein in Fanconi syndrome and design of an accurate immunoassay. Clin Chim Acta. 2012;413(3-4):483–489.
   Web of Science ®Google Scholar
• Tramonti G, Kanwar YS. Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy. Endocrine 2013;43(3):494–503.
   Web of Science ®Google Scholar
• del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14(3):179–187.
   PubMed Web of Science ®Google Scholar
• Zeni L, Norden AGW, Cancarini G, Unwin RJ. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30(6):701–717.
   PubMed Web of Science ®Google Scholar
• Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR. Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin Chem. 1987;33(6):775–779.
   Web of Science ®Google Scholar
• Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV Aids. 2010;5(6):524–530.
   Web of Science ®Google Scholar
• Campbell LJ, Dew T, Salota R, Cheserem E, Hamzah L, Ibrahim F, et al. Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol. 2012;13:85.
   Web of Science ®Google Scholar
• Fiseha T, Gebreweld A. Urinary markers of tubular injury in HIV-infected patients. Biochem Res Int. 2016;2016:1501785.
   Web of Science ®Google Scholar
• Hamzah L, Samarawickrama A, Campbell L, Pope M, Burling K, Walker-Bone K, et al. Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients. Aids. 2015;29(14):1785–1792.
   Web of Science ®Google Scholar
• Szymańska BM, Marchewka Z, Knysz B, Piwowar AB. A panel of urinary biochemical markers for the noninvasive detection of kidney dysfunction in HIV-infected patients . Pol Arch Intern Med. 2019;129(7-8):490–498.
   Google Scholar
• Norden AGW, Lapsley M, Unwin RJ. Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule. Adv Clin Chem. 2014;63:85–122.
   PubMed Web of Science ®Google Scholar
• Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O’Farrell S, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54(6):1034–1042.
   PubMed Web of Science ®Google Scholar
• Takano M, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Nishijima T, et al. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother. 2013;19(5):850–857.
   Web of Science ®Google Scholar
• Kabanda A, Vandercam B, Bernard A, Lauwerys R, van Ypersele de Strihou C. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 1996;27(6):803–808.
   Web of Science ®Google Scholar
• Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation. Antimicrob Agents Chemother. 2014;58(3):1294–1301.
   Web of Science ®Google Scholar
• Lepist E-I, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 2014;86(2):350–357.
   PubMed Web of Science ®Google Scholar
• German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. JAIDS J Acquir Immune Defic Syndr. 2012;61(1):32–40.
   PubMed Web of Science ®Google Scholar
• Lepist E-I, Phan TK, Roy A, Tong L, MacLennan K, Murray B, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409–5413.
   PubMed Web of Science ®Google Scholar
• Vinge E, Lindergård B, Nilsson–Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest. 1999;59(8):587–592.
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29.
   PubMed Web of Science ®Google Scholar
• Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990–996.
   PubMed Web of Science ®Google Scholar
• Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther. 2010;15(2):227–233.
   Web of Science ®Google Scholar
• Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1–infected patients: a systematic review and network meta-analysis. PLoS One. 2014;9(9):e105653.
   PubMed Web of Science ®Google Scholar
• Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211–219.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, DeJesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118–e120.
   PubMed Web of Science ®Google Scholar
• Bakal D, Coelho L, Luz P, Clark J, Veloso V, Lake J, et al. HIV-infected individuals using integrase inhibitors are at high risk of weight gain. Paper presented at: the 20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; 2018; New York.
   Google Scholar
• Hileman CO, Kinley B, Scharen-Guivel V, Melbourne K, Szwarcberg J, Robinson J, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor–based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis. 2015;212(3):345–354.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. The Lancet. 2010;375(9712):396–407.
   PubMed Web of Science ®Google Scholar
• Martínez E, D’Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315–2326.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, et al. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS. 2016;30(10):1563–1571.
   Web of Science ®Google Scholar